Structural analysis of inhibitor binding to human carbonic anhydrase II

X‐ray crystal structures of carbonic anhydrase II (CAII) complexed with sulfonamide inhibitors illuminate the structural determinants of high affinity binding in the nanomolar regime. The primary binding interaction is the coordination of a primary sulfonamide group to the active site zinc ion. Secondary interactions fine‐tune tight binding in regions of the active site cavity >5 Å away from zinc, and this work highlights three such features: (1) advantageous conformational restraints of a bicyclic thienothiazene‐6‐sulfonamide‐1,1‐dioxide inhibitor skeleton in comparison with a monocyclic 2,5‐thiophenedisulfonamide skeleton; (2) optimal substituents attached to a secondary sulfonamide group targeted to interact with hydrophobic patches defined by Phe131, Leu198, and Pro202; and (3) optimal stereochemistry and configuration at the C‐4 position of bicyclic thienothiazene‐6‐sulfonamides; the C‐4 substituent can interact with His64, the catalytic proton shuttle. Structure‐activity relationships rationalize affinity trends observed during the development of brinzolamide (AzoptTM), the newest carbonic anhydrase inhibitor approved for the treatment of glaucoma.

[1]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[2]  G. Whitesides,et al.  Secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase II influence inhibitor binding constants. , 1995, Journal of medicinal chemistry.

[3]  T. Maren,et al.  Carbonic anhydrase: General perspective and advances in glaucoma research , 1987 .

[4]  J J Baldwin,et al.  Application of the three-dimensional structures of protein target molecules in structure-based drug design. , 1994, Journal of medicinal chemistry.

[5]  J. Friedenwald The formation of the intraocular fluid. , 1949, American journal of ophthalmology.

[6]  A. Liljas,et al.  Structure of native and apo carbonic anhydrase II and structure of some of its anion-ligand complexes. , 1992, Journal of molecular biology.

[7]  J J Baldwin,et al.  Carbonic anhydrase inhibitors for the treatment of glaucoma , 2023, Медицинская этика.

[8]  J J Baldwin,et al.  Positions of His‐64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors , 1994, Protein science : a publication of the Protein Society.

[9]  Carol A. Fierke,et al.  Carbonic Anhydrase: Evolution of the Zinc Binding Site by Nature and by Design , 1996 .

[10]  A. Liljas,et al.  Refined structure of the acetazolamide complex of human carbonic anhydrase II at 1.9 A. , 1990, International Journal of Biological Macromolecules.

[11]  R. F. Chen,et al.  Combination of bovine carbonic anhydrase with a fluorescent sulfonamide. , 1967, The Journal of biological chemistry.

[12]  Mapping Protein-Peptide Affinity: Binding of Peptidylsulfonamide Inhibitors to Human Carbonic Anhydrase II , 1994 .

[13]  D. Silverman,et al.  The catalytic mechanism of carbonic anhydrase: implications of a rate-limiting protolysis of water , 1988 .

[14]  G. Petsko,et al.  Weakly polar interactions in proteins. , 1988, Advances in protein chemistry.

[15]  M. Karplus,et al.  Crystallographic R Factor Refinement by Molecular Dynamics , 1987, Science.

[16]  V. Kinsey Comparative chemistry of aqueous humor in posterior and anterior chambers of rabbit eye, its physiologic significance. , 1953, A.M.A. archives of ophthalmology.

[17]  A. Liljas,et al.  The structure of a complex between carbonic anhydrase II and a new inhibitor, trifluoromethane sulphonamide , 1994, FEBS letters.

[18]  S. Nair,et al.  Unexpected Ph-Dependent Conformation of His-64, the Proton Shuttle of Carbonic Anhydrase II. , 1992 .

[19]  D. Keilin,et al.  Sulphanilamide as a Specific Inhibitor of Carbonic Anhydrase , 1940, Nature.

[20]  G. Whitesides,et al.  Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors. , 1994, Journal of medicinal chemistry.

[21]  D. Silverman,et al.  Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: Molecular basis of isozyme‐drug discrimination , 1998, Protein science : a publication of the Protein Society.

[22]  M. Murcko,et al.  New isomeric classes of topically active ocular hypotensive carbonic anhydrase inhibitors: 5-substituted thieno[2,3-b]thiophene-2-sulfonamides and 5-substituted thieno[3,2-b]thiophene-2-sulfonamides. , 1991, Journal of medicinal chemistry.

[23]  D. Silverman,et al.  Role of histidine 64 in the catalytic mechanism of human carbonic anhydrase II studied with a site-specific mutant. , 1989, Biochemistry.

[24]  B. Becker Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, diamox; a preliminary report. , 1954, American journal of ophthalmology.